SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

A Wall Street Journal report noted that according to CNBC's David Faber, a prospective deal between Walgreens and New York ...

Inari Medical Inc (NARI) stock saw a modest uptick, ending the day at $79.74 which represents a slight increase of $0.28 or 0.35% from the prior close of $79.46. The stock opened at $79.54 and touched ...

JP Morgan has recently reduced Progyny Inc (PGNY) stock to Neutral rating, as announced on December 2, 2024, according to Finviz. Earlier, on November 13, 2024, Truist had reduced the stock from a Buy ...

The Wall Street Journal previously reported that Walgreens and Sycamore Partners were discussing a deal that could be ...

Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Analysts at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for 908 Devices in a note issued to ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...